Von Willebrand disease 2
MONDO:0013304Type 2 von Willebrand disease (type 2 VWD) is a form of VWD characterized by a bleeding disorder associated with a qualitative deficiency and functional anomalies of the Willebrand factor (von Willebrand factor; VWF).
Also known as: VWD2, von Willebrand disease 2, von Willebrand disease type 2, von Willebrand disease, types 2A, 2B, 2M, and 2N, von Willebrand's disease type 2, von willebrand's disease 2, VON WILLEBRAND disease, type 2, VWD, type 2
18 clinical trials for this condition and its sub-types, 4 tagged with Von Willebrand disease 2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Von Willebrand disease 2
-
Von Willebrand disease type 2A 2 trials
-
Von Willebrand disease type 2N 2 trials
-
Von Willebrand disease type 2B 1 trial
-
Von Willebrand disease type 2M 1 trial
-
New clotting factor combo aims to tame von willebrand bleeding
Disease control OngoingThis study looks at how well Eqwilate, a concentrated mix of two clotting proteins (VWF and FVIII), controls bleeding in people with von Willebrand disease. It includes patients aged 6 and older who use Eqwilate on demand, before surgery, or as regular prevention. Researchers tra…
Sponsor: Octapharma • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Trial for bleeding disorder drug in toddlers pulled before it started
Disease control CancelledThis study was designed to test how FANHDI, a clotting factor concentrate, works in children under 6 with severe von Willebrand disease (types 2 or 3). The goal was to measure how the drug moves through the body and how well it controls bleeding. However, the trial was withdrawn …
Phase 4 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
AI takes on blood clotting: can ChatGPT guide surgeons on bleeding?
Knowledge-focused CancelledThis study evaluates whether artificial intelligence models can accurately interpret ROTEM blood clotting tests and recommend treatments for coagulopathy. Researchers will compare AI decisions to those of a panel of clinical experts using data from adults undergoing elective card…
Sponsor: Ondokuz Mayıs University • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC